Bristol-Myers Squibb has revealed that a combination of its immunotherapies Opdivo and Yervoy was superior to chemo alone in keeping disease progression at bay in patients with non-small cell lung cancer (NSCLC).
News
Pfizer/Astellas’ Xtandi cuts risk of prostate cancer spread
Adding Pfizer and Astellas Pharma’s Xtandi to hormone therapy significantly cut the risk of prostate cancer spreading compared to hormone therapy alone, trial findings show.
VCCP Health wins record 10 Golds at PM Society Awards
VCCP Health has cleaned up at year’s PM Society Awards, taking home a record 10 Gold gongs, as well as three Silver and three Bronze awards, for its work across pharmaceutical and healthcare advertising and communications.
LIG Biowise raises £1.8m for rapid diagnostic kit
Manchester, UK-based LIG Biowise has raised £1.8 million in Series A fundraising, to further develop its ultra-rapid diagnostic device.
GP workforce in ‘precarious state’, warns RCGP
A small study involving GPs based in the South West has revealed the key factors driving a large number of doctors out of the profession, prompting GPs leaders to warn that the workforce is in a “precarious state”.
UK breast cancer deaths drop 10 percent in five years
Breast cancer mortality rates have dropped 10 percent in five years, according to the latest analysis of data by Cancer Research UK.
Experts call for ring-fenced health and social care tax
Health experts are calling for a ring-fenced tax to help plug the huge gaps in NHS and social care budgets.
Stage 2 entries up by 55% – Clinical Researcher of the Year – The Americas
This highly prestigious competition for clinical researchers in the Americas is now closed for entry.
PharmaTimes Media has reported a surge in entrants to this year’s Clinical Researcher of the Year competition, with over 45% more applicants passing the MCQ than in 2017.
PharmaTimes International Clinical Researcher of the Year: Entries close on a high
PharmaTimes Media has reported a substantial increase in the number of MCQ passes and essay submissions for this year’s International Clinical Researcher of the Year competition.
Zebinix non-inferior to current standard of care in epilepsy
Eisai and Bial’s epilepsy drug Zebinix has shown effectiveness on par with that of the current standard of care in newly diagnosed focal epilepsy patients.
Prostate cancer now third biggest cancer killer in the UK
The number of men dying from prostate cancer has overtaken the number of women dying from breast cancer for the first time, with the disease now the UK’s third biggest cancer killer.
AZ books 3 percent sales rise for Q4
Anglo-Swedish drugs giant AstraZeneca has booked a 3 percent rise in fourth-quarter sales to $5.8 billion, after growth in product sales was recorded following a number of years of decline.
Breast cancer patients barred from NHS access to Faslodex
The National Institute for Health and Care has issued final guidelines rejecting AstraZeneca’s Faslodex for certain patients with breast cancer.
Sanofi, DNDi seek EMA review for sleeping sickness drug
Sanofi has asked European regulators to review an experimental medicine being developed in partnership with the Drugs for Neglected Disease initiative (DNDi) for sleeping sickness, which is endemic in Africa.
NICE backs Roche’s Perjeta for breast cancer
The National Institute for Health and Care Excellence has issued a final green light securing routine NHS funding for Roche’s Perjeta in patients with a certain type of breast cancer.
